UBE2T在原发性肝癌中的表达及临床意义

doi:10.11904/j.issn.1002-3070.2019.02.006

实用肿瘤学杂志 ›› 2019, Vol. 33 ›› Issue (2): 128-133.doi: 10.11904/j.issn.1002-3070.2019.02.006

UBE2T在原发性肝癌中的表达及临床意义

石小康^1,2, 丁佑铭^1,2, 汪斌^1,2, 余斌^1,2, 徐雨^1,2

1.武汉大学人民医院肝胆腔镜外科(武汉 430060);
2.消化系统疾病湖北省重点实验室

收稿日期:2018-06-25 修回日期:2018-11-28 出版日期:2019-04-20 发布日期:2019-04-25
通讯作者: 丁佑铭,E-mail:dingym@whu.edu.cn
作者简介:石小康,男,(1994-),硕士研究生,从事肝脏肿瘤基础与临床方面的研究

Expression and clinical significance of UBE2T in primary liver cancer

SHI Xiaokang^{1, 2}, DING Youming^{1, 2}, WANG Bin^{1, 2}, YU Bin^{1, 2}, XU Yu^{1, 2}

1.Department of Hepatobiliary and Laparoscopic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China;
2.Hubei key laboratory of Digestive System Disease

Received:2018-06-25 Revised:2018-11-28 Online:2019-04-20 Published:2019-04-25

摘要/Abstract

摘要： 目的分析泛素结合酶E2T(Ubiquitin-conjugating enzyme E2T,UBE2T)在原发性肝癌中的表达及其与肝癌患者临床病理学参数和预后的关系。方法从癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库下载正常肝组织和肝癌组织中UBE2T基因mRNA二代测序数据及临床病理资料,分析UBE2T在癌组织和正常组织中的表达差异,阐明UBE2T mRNA表达水平与肝癌患者临床病理学参数的相关关系。采用Kaplan-Meier进行预后分析,利用Cox比列风险回归模型研究与肝癌患者预后相关的因素,并根据基因集富集分析(Gene set enrichment analysis,GSEA)结果预测UBE2T参与肝癌发生、发展的可能调控通路。结果 UBE2T mRNA在肝癌组织中表达明显高于癌旁组织(P＜0.01);UBE2T高表达与Grade分级、TNM分期、有无血管侵袭等密切相关(P＜0.01),且提示肝癌患者的预后不良;TNM分期、血管侵袭、UBE2T表达水平均是影响肝癌患者预后的独立危险因素。结论 UBE2T的高表达与肝癌患者的临床病理因素及预后显著相关,可以作为潜在的判断肝癌患者预后的标志物和肿瘤治疗的靶标。

关键词: 泛素结合酶E2T, 癌, 肝细胞, 癌症基因组图谱(TCGA), 预后

Abstract: Objective The objective of this study was to analyze the expression of ubiquitin-conjugating enzyme E2T(UBE2T)in primary liver cancer and its relationship with clinicopathological parameters and prognosis of patients with liver cancer. Methods The second generation sequencing data and clinical pathological data of UBE2T gene mRNA in normal liver tissues and liver cancer tissues were downloaded from the Cancer Genome Atlas(TCGA)database.The expression of UBE2T in cancer tissues and normal tissues was analyzed to elucidate the relationship between UBE2T at mRNA level and clinicopathological parameters of patients with liver cancer.Kaplan-Meier was used for prognostic analysis.The Cox proportional hazard regression model was performed for the multivariate analysis of the prognostic factors associated with HCC.Based on the results of gene set enrichment analysis(GSEA),UBE2T was involved in the possible regulating pathways of HCC development. Results The expression of UBE2T at mRNA level in hepatocarcinoma tissues was significantly higher than that in adjacent tissues(P＜0.01).The high expression of UBE2T was closely related to pathological grade,TNM staging,and vascular invasion(P＜0.01),suggesting a poor prognosis of patients with liver cancer.Multivariate Cox regression analysis showed that TNM staging,vascular invasion and UBE2T expression were independent risk factors affecting the prognosis of patients with liver cancer. Conclusion The high expression of UBE2T is significantly associated with the clinicopathological factors and prognosis of patients with liver cancer.It can be used as a potential marker for predicting the prognosis of liver cancer patients and a target for tumor therapy.

Key words: UBE2T, Carcinoma, Hepatocellular, The cancer genome atlas(TCGA), Prognosis

中图分类号:

R735.7

石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.

SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.

参考文献

1 Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):69-90.
2 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
3 Zeng H,Zheng R,Guo Y,et al.Cancer survival in China,2003-2005:A population‐based study[J].Int J Cancer,2015,136(8):1921-1930.
4 Perezpe?a J,Corralessánchez V,Amir E,et al.Ubiquitin-conjugating enzyme E2T(UBE2T)and denticleless protein homolog(DTL)are linked to poor outcome in breast and lung cancers[J].Sci Rep,2017,7(1):17530-17537.
5 Luo C,Yao Y,Yu Z,et al.UBE2T knockdown inhibits gastric cancer progression[J].Oncotarget,2017,8(20):32639-32654.
6 Mingxin W,Yongwon K,Yongsheng W,et al.Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer[J].Oncotarget,2015,6(28):25226-25239.
7 Gong YQ,Peng D,Ning XH,et al.UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells[J].Oncol Lett,2016,12(6):4485-4492.
8 Liu LP,Yang M,Peng QZ,et al.UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53[J].Biochem Biophys Res Commun,2017,493(1):20-27.
9 Allaire M,Nault JC.Advances in management of hepatocellular carcinoma[J].Curr Opin Oncol,2017,29(4):288-295.
10 Hu W,Xiao L,Cao C,et al.UBE2T promotes nasopharyngeal carcinoma cell proliferation,invasion,and metastasis by activating the AKT/GSK3β/β-catenin pathway[J].Oncotarget,2016,7(12):15161-15172.
11 Ueki T,Park JH,Nishidate T,et al.Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells[J].Cancer Res,2009,69(22):8752-8760.
12 周春芳,赵珊珊,孙泽群,等.酸性环境诱导肝癌HePG2细胞EMT[J].实用肿瘤学杂志,2017,31(3):199-204.
13 Zijl FV,Zulehner G,Petz M,et al.Epithelial-mesenchymal transition in hepatocellular carcinoma[J].Future Oncology,2009,5(8):1169-1179.
14 Huang MT,Wei PL,Liu JJ,et al.Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression[J].Ann Surg Oncol,2010,17(12):3379-3385.
15 Luo C,Yao Y,Yu Z,et al.UBE2T knockdown inhibits gastric cancer progression[J].Oncotarget,2017,8(20):32639-32654.
16 Mingxin W,Yongwon K,Yongsheng W,et al.Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer[J].Oncotarget,2015,6(28):25226-25239.
17 曹传辉.泛素结合酶UBE2T在肝细胞癌发生发展中的作用及其机制的初步探讨[D].广州:南方医科大学,2013.
18 刘腾飞,刘小琴,葛超,等.泛素结合酶UBE2T基因在肝癌细胞迁移和侵袭中的作用及其临床意义[J].肿瘤,2018,38(5):408-418.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[4]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[5]	秦文,赵楠楠,韩永焕,徐亚君. ZNF436在胃癌中的表达及调控WNT/β-catenin对胃癌细胞迁移及侵袭的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 222-227.
[6]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[7]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[8]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[9]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[10]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[11]	张彦秋,韩阿蒙,李金旺,顾涛,付占昭,毛羽,张子健,杨振. CRT+ARC技术在局部晚期肺癌患者中临床应用的初步研究[J]. 实用肿瘤学杂志, 2019, 33(3): 256-260.
[12]	李珊,赵春波,乔文波. 术中放疗在胰腺癌中的应用进展[J]. 实用肿瘤学杂志, 2019, 33(3): 280-283.
[13]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[14]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[15]	吕博文, 钱钧, 王杰, 钱景荣, 卢莹莹, 苏丽菊, 杨桐树, 李文辉. miR-455-5p在上皮性卵巢癌中表达研究及其靶基因功能分析[J]. 实用肿瘤学杂志, 2019, 33(2): 115-121.

UBE2T在原发性肝癌中的表达及临床意义

Expression and clinical significance of UBE2T in primary liver cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价